AssetMark Inc’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.85M | Buy |
12,594
+278
| +2% | +$189K | 0.01% | 618 |
|
|
2026
Q1 | $9.52M | Buy |
12,316
+1,036
| +9% | +$793K | 0.02% | 517 |
|
|
2025
Q4 | $8.71M | Sell |
11,280
-9,539
| -46% | -$6.48M | 0.02% | 525 |
|
|
2025
Q3 | $11.7M | Sell |
20,819
-106,802
| -84% | -$60.4M | 0.03% | 411 |
|
|
2025
Q2 | $67M | Buy |
127,621
+23,988
| +23% | +$13.4M | 0.16% | 118 |
|
|
2025
Q1 | $65.7M | Buy |
103,633
+2,658
| +3% | +$1.83M | 0.18% | 112 |
|
|
2024
Q4 | $71.9M | Sell |
100,975
-3,005
| -3% | -$2.52M | 0.2% | 96 |
|
|
2024
Q3 | $109M | Buy |
103,980
+8,289
| +9% | +$9.22M | 0.31% | 60 |
|
|
2024
Q2 | $101M | Buy |
95,691
+1,521
| +2% | +$1.47M | 0.31% | 63 |
|
|
2024
Q1 | $90.6M | Buy |
94,170
+1,999
| +2% | +$1.9M | 0.29% | 74 |
|
|
2023
Q4 | $81M | Buy |
92,171
+1,552
| +2% | +$1.28M | 0.29% | 67 |
|
|
2023
Q3 | $74.6M | Buy |
90,619
+9,980
| +12% | +$7.84M | 0.3% | 73 |
|
|
2023
Q2 | $57.9M | Buy |
80,639
+5,581
| +7% | +$4.3M | 0.23% | 103 |
|
|
2023
Q1 | $61.7M | Buy |
75,058
+5,214
| +7% | +$3.93M | 0.26% | 83 |
|
|
2022
Q4 | $50.4M | Buy |
69,844
+2,610
| +4% | +$1.93M | 0.22% | 100 |
|
|
2022
Q3 | $46.3M | Sell |
67,234
-653
| -1% | -$411K | 0.22% | 99 |
|
|
2022
Q2 | $40.1M | Sell |
67,887
-4,981
| -7% | -$3.24M | 0.18% | 121 |
|
|
2022
Q1 | $50.9M | Buy |
72,868
+10,903
| +18% | +$6.9M | 0.21% | 108 |
|
|
2021
Q4 | $39.1M | Buy |
61,965
+2,032
| +3% | +$1.25M | 0.16% | 140 |
|
|
2021
Q3 | $36.3M | Sell |
59,933
-1,010
| -2% | -$627K | 0.16% | 140 |
|
|
2021
Q2 | $34M | Sell |
60,943
-2,192
| -3% | -$1.11M | 0.16% | 146 |
|
|
2021
Q1 | $29.9M | Buy |
63,135
+5,495
| +10% | +$2.68M | 0.15% | 145 |
|
|
2020
Q4 | $27.8M | Buy |
57,640
+25,650
| +80% | +$13.8M | 0.16% | 141 |
|
|
2020
Q3 | $17.9M | Buy |
31,990
+30,843
| +2,689% | +$18.7M | 0.12% | 158 |
|
|
2020
Q2 | $715K | Buy |
1,147
+1,103
| +2,507% | +$626K | 0.01% | 351 |
|
|
2020
Q1 | $21K | Buy |
+44
| New | +$18.1K | ﹤0.01% | 864 |
|
|
2019
Q4 | – | Sell |
-3,887
| Closed | -$1.08M | – | 1466 |
|
|
2019
Q3 | $1.08M | Buy |
3,887
+3,868
| +20,358% | +$1.14M | 0.01% | 308 |
|
|
2019
Q2 | $6K | Sell |
19
-190
| -91% | -$63.3K | ﹤0.01% | 1034 |
|
|
2019
Q1 | $86K | Sell |
209
-57
| -21% | -$23.5K | ﹤0.01% | 610 |
|
|
2018
Q4 | $99K | Buy |
266
+33
| +14% | +$12.1K | ﹤0.01% | 561 |
|
|
2018
Q3 | $94K | Buy |
233
+155
| +199% | +$59K | ﹤0.01% | 595 |
|
|
2018
Q2 | $27K | Buy |
78
+15
| +24% | +$4.69K | ﹤0.01% | 858 |
|
|
2018
Q1 | $22K | Sell |
63
-27
| -30% | -$9.39K | ﹤0.01% | 922 |
|
|
2017
Q4 | $34K | Buy |
90
+29
| +48% | +$11.7K | ﹤0.01% | 878 |
|
|
2017
Q3 | $27K | Buy |
61
+6
| +11% | +$2.85K | ﹤0.01% | 855 |
|
|
2017
Q2 | $27K | Sell |
55
-4
| -7% | -$1.75K | ﹤0.01% | 841 |
|
|
2017
Q1 | $23K | Buy |
59
+12
| +26% | +$4.45K | ﹤0.01% | 830 |
|
|
2016
Q4 | $17K | Buy |
47
+3
| +7% | +$1.14K | ﹤0.01% | 899 |
|
|
2016
Q3 | $18K | Buy |
44
+9
| +26% | +$3.61K | ﹤0.01% | 885 |
|
|
2016
Q2 | $12K | Sell |
35
-26
| -43% | -$10K | ﹤0.01% | 945 |
|
|
2016
Q1 | $22K | Buy |
61
+39
| +177% | +$16.1K | ﹤0.01% | 744 |
|
|
2015
Q4 | $12K | Buy |
22
+15
| +214% | +$8.13K | ﹤0.01% | 862 |
|
|
2015
Q3 | $3K | Hold |
7
| – | – | ﹤0.01% | 618 |
|
|
2015
Q2 | $4K | Buy |
+7
| New | +$3.42K | ﹤0.01% | 598 |
|
Other funds holding REGN
MCI
AssetMark Inc's REGN Position: Q2 2026 in Review
AssetMark Inc increased its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q2 2026, buying an estimated $189K and bringing the position to 12,594 shares worth $7.85M. The position accounts for 0.01% of the portfolio, ranked #618.
AssetMark Inc first reported a position in REGN in Q2 2015 and has held it in 44 quarters since. The position peaked at $109M in Q3 2024. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- AssetMark Inc held 12,594 shares of Regeneron Pharmaceuticals worth $7.85M as of Q2 2026.
- AssetMark Inc bought 278 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $189K.
- Regeneron Pharmaceuticals made up 0.01% of AssetMark Inc's portfolio in Q2 2026, its #618 holding.
- AssetMark Inc first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
- AssetMark Inc's Regeneron Pharmaceuticals position peaked at $109M in Q3 2024.
- 518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.